Gu Ruizhi, Qin Fu-Ying, Wang Luxuan, Zhang Jiaojiao, Emerson Jacob, Ma Qing, Lu Jie, Anderson Karl E, Wang Junmei, Ma Xiaochao
Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
Computational Chemical Genomics Screening Center, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
Drug Metab Dispos. 2025 Jul;53(7):100105. doi: 10.1016/j.dmd.2025.100105. Epub 2025 May 27.
Erythropoietic protoporphyria (EPP) is caused by loss-of-function mutations in ferrochelatase (FECH), leading to the accumulation of its substrate, protoporphyrin IX (PPIX). PPIX is primarily produced in the bone marrow and transported to the liver for excretion. Because PPIX is hydrophobic, its elevated levels can cause bile duct blockage, cholestatic liver injury, and even liver failure. However, the specific transporter responsible for PPIX uptake into hepatocytes remains unclear. The OATP1B1/1B3 transporters, which are expressed in hepatocytes, facilitate the uptake of coproporphyrin III, a structural analog of PPIX. Additionally, OATP1B1/1B3 mediates the uptake of bilirubin, a biomarker of liver injury, from plasma into the liver for excretion. Therefore, we aimed to determine the role of OATP1B1/1B3 in regulating PPIX and bilirubin homeostasis under EPP conditions. A mouse strain carrying a Fech mutation was used as an EPP model. Building on this, we generated a new EPP mouse model with Oatp1a/1b deficiency. Using these EPP mouse models, along with OATP1B1/1B3-overexpressing cells, our study revealed that PPIX is not a substrate of OATP1B1/1B3. Notably, our work found that genetic deficiency or pharmacologic suppression of Oatp1a/1b exacerbates hyperbilirubinemia in EPP mice without worsening liver injury. Mechanistically, Oatp1a/1b deficiency impairs bilirubin uptake from plasma, while Fech deficiency leads to PPIX-mediated bile duct blockage and reduced bilirubin excretion, synergistically exacerbating hyperbilirubinemia. In summary, our work demonstrated that deficiency or suppression of Oatp1a/1b exacerbates hyperbilirubinemia in EPP mouse models, suggesting that assessment of OATP1B1/1B3 function is crucial in EPP patients with EPP with hyperbilirubinemia. SIGNIFICANCE STATEMENT: This work revealed that serum bilirubin levels are not paralleled with liver damage in the erythropoietic protoporphyria mouse models with Oatp1a/1b deficiency. Our findings suggest that assessment of OATP1B1/1B3 function is crucial in patients with erythropoietic protoporphyria with hyperbilirubinemia.
红细胞生成性原卟啉病(EPP)由亚铁螯合酶(FECH)功能丧失性突变引起,导致其底物原卟啉IX(PPIX)蓄积。PPIX主要在骨髓中产生,并转运至肝脏进行排泄。由于PPIX具有疏水性,其水平升高可导致胆管阻塞、胆汁淤积性肝损伤,甚至肝衰竭。然而,负责PPIX摄取进入肝细胞的具体转运体仍不清楚。在肝细胞中表达的有机阴离子转运多肽1B1/1B3(OATP1B1/1B3)转运体促进粪卟啉III(PPIX的结构类似物)的摄取。此外,OATP1B1/1B3介导肝损伤生物标志物胆红素从血浆摄取进入肝脏进行排泄。因此,我们旨在确定OATP1B1/1B3在EPP条件下调节PPIX和胆红素稳态中的作用。携带Fech突变的小鼠品系用作EPP模型。在此基础上,我们构建了一种新的Oatp1a/1b缺陷型EPP小鼠模型。利用这些EPP小鼠模型以及过表达OATP1B1/1B3的细胞,我们的研究表明PPIX不是OATP1B1/1B3的底物。值得注意的是,我们的研究发现,Oatp1a/1b的基因缺陷或药物抑制会加重EPP小鼠的高胆红素血症,而不会加重肝损伤。从机制上讲,Oatp1a/1b缺陷会损害胆红素从血浆中的摄取,而Fech缺陷会导致PPIX介导的胆管阻塞和胆红素排泄减少,协同加重高胆红素血症。总之,我们的研究表明,Oatp1a/1b的缺陷或抑制会加重EPP小鼠模型中的高胆红素血症,这表明评估OATP1B1/1B3功能在伴有高胆红素血症的EPP患者中至关重要。意义声明:这项研究揭示,在Oatp1a/1b缺陷的红细胞生成性原卟啉病小鼠模型中,血清胆红素水平与肝损伤不平行。我们的研究结果表明,评估OATP1B1/1B3功能在伴有高胆红素血症的红细胞生成性原卟啉病患者中至关重要。